Poniard Pharmaceuticals, Inc. (PARD) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Poniard Pharmaceuticals, Inc. (PARD) trades at $0.0001 with AI Score 48/100 (Grade C). Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing platinum-based cancer treatments. Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for PARD: PARD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PARD against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PARD: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Poniard Pharmaceuticals, Inc. (PARD) Healthcare & Pipeline Overview
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing platinum-based cancer treatments. Its lead product candidate, Picoplatin, has advanced through pivotal Phase III trials for small cell lung cancer and Phase II studies for colorectal and prostate cancers, alongside a Phase I oral formulation, aiming to address critical unmet needs in oncology.
What Is the Investment Thesis for PARD?
Poniard Pharmaceuticals, Inc. presents a research-stage profile centered on its lead candidate, Picoplatin, a platinum-based therapy for various cancers. The company's strategic value proposition is derived from the advanced clinical development of Picoplatin, notably its pivotal Phase III SPEAR trial for second-line small cell lung cancer, alongside Phase II studies for metastatic colorectal and hormone-refractory prostate cancers. These completed trials represent significant milestones in de-risking the therapeutic candidate, providing a foundation for potential future regulatory submissions and market entry. The exploration of an oral formulation in Phase I also indicates a commitment to expanding Picoplatin's utility and patient accessibility. With a market capitalization of $0.00B and a small team of 7 employees, Poniard operates as a highly focused entity, concentrating its resources on the advancement of this singular asset. The company's long operational history, founded in 1984, underscores its enduring dedication to biopharmaceutical development. The potential for Picoplatin to address multiple oncology indications, if successful, could unlock significant value within the substantial global cancer therapeutics market. Future value drivers would hinge on positive clinical outcomes, successful regulatory approvals, and strategic partnerships for commercialization.
Based on FMP financials and quantitative analysis
PARD Key Highlights
Market capitalization of $0.00B, reflecting its early-stage development focus and lean operational structure.
- Beta of -36.63, indicating an unusual and potentially highly volatile or thinly traded stock characteristic.
- Does not pay a dividend, consistent with a biopharmaceutical company in the research and development phase.
- Operates with a small team of 7 employees, emphasizing a highly focused and specialized operational model.
- Primary strategic asset is Picoplatin, a platinum-based cancer therapy that has advanced through pivotal Phase III clinical trials.
Who Are PARD's Competitors?
PARD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PARD's Key Strengths?
Dedicated focus on a single, advanced-stage product candidate, Picoplatin, across multiple cancer types.
- Picoplatin has progressed through significant clinical milestones, including a pivotal Phase III trial.
- Long operational history, founded in 1984, indicating experience in biopharmaceutical development.
- Exploration of an oral formulation for Picoplatin, potentially enhancing patient convenience and market appeal.
What Are PARD's Weaknesses?
High dependence on the success of a single product candidate, Picoplatin, for future viability.
- Extremely small team of 7 employees, potentially limiting operational scale and speed.
- Market capitalization of $0.00B, suggesting significant funding challenges and limited financial resources.
- Operates on the OTC market with an 'Unknown' disclosure status, leading to transparency and liquidity issues.
What Could Drive PARD Stock Higher?
PARD catalyst: Strategic evaluation of Picoplatin's comprehensive clinical data, including Phase III SPEAR trial results, to determine optimal regulatory pathways and market entry strategies for its various indications.
- Potential announcements regarding partnerships or licensing agreements to support the further development or commercialization of Picoplatin in global markets.
- Continued research and development efforts focused on platinum-based cancer therapies, potentially exploring new formulations or combination strategies for Picoplatin.
What Are the Key Risks for PARD?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Significant financial risk associated with a $0.00B market capitalization and the absence of a dividend, indicating potential funding challenges for ongoing operations and future development.
- Failure to secure regulatory approvals for Picoplatin, even after advanced clinical trials, due to efficacy, safety, or manufacturing concerns.
- High dependence on the success of a single product candidate, Picoplatin, meaning any setbacks could severely impact the company's viability.
- Intense competition within the oncology therapeutics market from established pharmaceutical companies and other biotechs developing novel cancer treatments.
- Operational risks inherent in managing a lean team of 7 employees, potentially limiting the scope and speed of development and commercialization efforts.
What Are the Growth Opportunities for PARD?
- **Advancement in Small Cell Lung Cancer (SCLC) Treatment:** Poniard's flagship product candidate, Picoplatin, has undergone a pivotal Phase III SPEAR trial for the second-line treatment of small cell lung cancer. SCLC remains a challenging cancer with high recurrence rates and limited effective second-line options, representing a significant unmet medical need. Successful outcomes from this advanced trial could position Picoplatin for regulatory approval, offering a new therapeutic avenue for patients who have progressed on initial therapies. The global SCLC market, while niche compared to non-small cell lung cancer, still represents a substantial patient population seeking improved survival and quality of life.
- **Expansion into Metastatic Colorectal Cancer (mCRC):** Picoplatin has also been investigated in Phase II trials as a first-line treatment for metastatic colorectal cancer. mCRC is a prevalent and aggressive gastrointestinal cancer, with a large patient population globally. The development of new first-line agents, particularly those with a platinum backbone, could provide clinicians with additional tools to combat disease progression. Positive results from these Phase II studies could pave the way for further clinical development, potentially leading to market entry in a broad and competitive therapeutic area, addressing a critical need for effective initial treatment strategies.
- **Targeting Hormone-Refractory Prostate Cancer (HRPC):** The company has conducted Phase II studies evaluating Picoplatin for hormone-refractory prostate cancer, also known as castration-resistant prostate cancer. HRPC represents an advanced stage of prostate cancer where hormonal therapies are no longer effective, necessitating alternative treatment approaches. The market for HRPC therapies is substantial, driven by an aging global population and the increasing incidence of prostate cancer. Successful progression of Picoplatin in this indication could offer a valuable treatment option for patients with limited choices, potentially improving outcomes in a challenging disease setting.
- **Development of an Oral Formulation for Solid Tumors:** Poniard has explored an oral formulation of Picoplatin in a Phase I study for solid tumors. An oral chemotherapy option offers significant advantages in terms of patient convenience, reduced need for intravenous administration, and potential for at-home treatment, which can enhance compliance and quality of life. If further developed and proven effective, an oral Picoplatin could significantly broaden its market applicability across various solid tumor types, potentially capturing a larger share of the oncology market by offering a more patient-friendly delivery method.
- **Strategic Partnerships and Licensing Opportunities:** Given Poniard's focused operational model and its advanced clinical asset, Picoplatin, there is a potential growth opportunity in forming strategic partnerships or licensing agreements. Collaborations with larger pharmaceutical companies could provide the necessary resources for extensive global commercialization, manufacturing, and further pipeline expansion. Such partnerships could accelerate market penetration, leverage established sales channels, and provide non-dilutive funding for Poniard, maximizing the value of Picoplatin across its multiple indications and potentially exploring new therapeutic areas.
What Threats Does PARD Face?
- Risk of clinical trial failures or unfavorable results, which could halt Picoplatin's development.
- Intense competition from larger pharmaceutical companies and other biotechs in the oncology market.
- Significant regulatory hurdles and potential delays in obtaining market approval for Picoplatin.
- Ongoing need for substantial funding to complete development and commercialization, given its current financial profile.
- Risks associated with OTC trading, including low liquidity and limited investor confidence.
What Are PARD's Competitive Advantages?
- Proprietary drug candidate, Picoplatin, a platinum-based therapy with specific targeting potential.
- Advanced clinical trial data, including a pivotal Phase III trial for small cell lung cancer, representing significant development investment.
- Focus on multiple distinct cancer indications, potentially broadening market reach if successful.
- Specialized expertise in platinum-based chemotherapy development.
What Does PARD Do?
Poniard Pharmaceuticals, Inc., founded in 1984 as NeoRx Corporation, has evolved into a biopharmaceutical entity dedicated to the discovery and market introduction of innovative cancer treatments. The company, which rebranded to its current name in September 2006, operates from its headquarters in Seattle, Washington, with a lean team of 7 employees. Its core strategic focus revolves around its flagship product candidate, Picoplatin. Picoplatin is a platinum-based therapeutic agent designed to target and treat a range of aggressive cancer types. These include small cell lung cancer, metastatic colorectal cancer, hormone-refractory prostate cancer, and ovarian cancers, representing significant areas of unmet medical need within oncology. Poniard has systematically advanced Picoplatin through various rigorous clinical development stages. This includes the completion of a pivotal Phase III SPEAR trial, which evaluated Picoplatin for the second-line treatment of patients diagnosed with small cell lung cancer. This advanced stage of clinical investigation signifies a substantial commitment to bringing this therapy to market for a challenging indication. Furthermore, the company has conducted Phase II studies to explore Picoplatin's efficacy as a first-line treatment for metastatic colorectal cancer, a disease with complex treatment paradigms. Concurrently, Phase II trials also investigated its potential in hormone-refractory prostate cancer, another area requiring effective therapeutic options. In addition to intravenous formulations, Poniard has explored alternative delivery methods, evidenced by an early-stage Phase I trial examining an oral formulation of Picoplatin for solid tumors, which could offer enhanced patient convenience and broader applicability. Through these extensive clinical development efforts, Poniard Pharmaceuticals, Inc. aims to establish Picoplatin as a valuable addition to the cancer treatment landscape, leveraging its platinum-based mechanism of action to improve patient outcomes across multiple oncology indications.
What Products and Services Does PARD Offer?
- Develops and aims to commercialize cancer therapeutics.
- Focuses on its lead product candidate, Picoplatin, a platinum-based cancer therapy.
- Targets multiple cancer indications including small cell lung, colorectal, prostate, and ovarian cancers.
- Has conducted a pivotal Phase III SPEAR trial for second-line small cell lung cancer.
- Evaluated Picoplatin in Phase II trials for first-line metastatic colorectal cancer.
- Investigated Picoplatin in Phase II trials for hormone-refractory prostate cancer.
- Explored an oral formulation of Picoplatin in a Phase I study for solid tumors.
- Operates as a biopharmaceutical company from Seattle, Washington.
How Does PARD Make Money?
- Primarily engaged in the research and development of novel cancer treatments.
- Aims to bring its lead product candidate, Picoplatin, through clinical trials to market introduction.
- Potential future revenue generation from the commercialization or licensing of Picoplatin.
- Relies on funding to support extensive clinical development stages for its drug pipeline.
What Industry Does PARD Operate In?
Poniard Pharmaceuticals, Inc. operates within the highly competitive and innovation-driven biotechnology sector, specifically focusing on oncology therapeutics. The cancer treatment market is characterized by continuous research and development, aiming to address diverse and often aggressive disease types. Platinum-based therapies, like Poniard's Picoplatin, represent a foundational class of chemotherapy agents, and ongoing efforts focus on improving their efficacy, safety profile, and delivery methods. Poniard's strategy positions it as a developer of a potentially differentiated platinum compound, targeting indications such as small cell lung, colorectal, prostate, and ovarian cancers, which collectively represent significant patient populations and market opportunities. The industry landscape includes numerous large pharmaceutical companies and smaller biotechs developing novel chemotherapies, targeted therapies, immunotherapies, and combination regimens. Poniard's advancement of Picoplatin through Phase III and Phase II trials places it among companies with late-stage assets, seeking to carve out a niche by offering an alternative or improved treatment option within established therapeutic areas.
Who Are PARD's Key Customers?
- Patients suffering from various cancer types, including small cell lung, colorectal, prostate, and ovarian cancers.
- Oncology specialists and healthcare providers seeking new treatment options for their patients.
- The broader global oncology market, addressing unmet medical needs in cancer therapy.
Financial Health
Poniard Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Poniard Pharmaceuticals, Inc. (PARD) Valuation Context
Relative to its peer group, PARD's quantitative score of 48/100 is below the peer average of 76/100.
Company Profile
Poniard Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO Robert F. Caspari. PARD has traded publicly since 1988.
Earnings Track Record
Poniard Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 7.1% above estimates on average.
Insider Activity
The most recent 12 insider filings for Poniard Pharmaceuticals, Inc. break down as 7 sales and 5 purchases. On net that is roughly 8K shares disposed (about $7K), a signal worth weighing alongside the fundamentals.
PARD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Dedicated focus on a single, advanced-stage product candidate, Picoplatin, across multiple cancer types.
- Picoplatin has progressed through significant clinical milestones, including a pivotal Phase III trial.
- Long operational history, founded in 1984, indicating experience in biopharmaceutical development.
- Exploration of an oral formulation for Picoplatin, potentially enhancing patient convenience and market appeal.
Bear Case
- High dependence on the success of a single product candidate, Picoplatin, for future viability.
- Extremely small team of 7 employees, potentially limiting operational scale and speed.
- Market capitalization of $0.00B, suggesting significant funding challenges and limited financial resources.
- Operates on the OTC market with an 'Unknown' disclosure status, leading to transparency and liquidity issues.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
PARD Latest News
No recent news available for PARD.
PARD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PARD.
Price Targets
Wall Street price target analysis for PARD.
PARD MoonshotScore
What does this score mean?
The MoonshotScore rates PARD 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Robert F. Caspari
CEO
Robert F. Caspari serves as the CEO of Poniard Pharmaceuticals, Inc., leading a dedicated team of 7 employees. His role involves overseeing the strategic direction and operational execution for the biopharmaceutical company, which is focused on the discovery and market introduction of cancer treatments. Caspari's leadership is central to guiding the development of the company's flagship product candidate, Picoplatin, through its various clinical stages. While specific details regarding his prior career history, educational background, or previous executive roles are not provided in the available information, his current position indicates responsibility for the company's biopharmaceutical development efforts and corporate management.
Track Record: Under Robert F. Caspari's leadership, Poniard Pharmaceuticals, Inc. has maintained its focus on advancing Picoplatin, its platinum-based cancer therapy. Key milestones include the progression of Picoplatin through a pivotal Phase III SPEAR trial for small cell lung cancer and its evaluation in Phase II studies for metastatic colorectal and hormone-refractory prostate cancers. Caspari's management of the 7-employee team has ensured the continued dedication to these clinical development programs, reflecting a sustained commitment to the company's mission of bringing cancer treatments to market.
PARD OTC Market Information
Poniard Pharmaceuticals, Inc. trades on the OTC market under the "OTC Other" tier. This classification signifies that the company does not meet the listing requirements for higher OTC tiers like OTCQX or OTCQB, nor for major exchanges such as the NYSE or NASDAQ. Companies in the "OTC Other" tier typically have limited public disclosure, often providing minimal or no financial reporting to the SEC or OTC Markets Group. This contrasts sharply with companies on major exchanges or even higher OTC tiers, which are subject to stringent reporting standards, including regular audited financial statements, offering greater transparency to investors.
- OTC Tier: OTC Other
- Lack of transparent financial reporting due to "Unknown" disclosure status, hindering informed investment decisions.
- Extremely low trading liquidity and wide bid-ask spreads, making it difficult to buy or sell shares efficiently.
- Increased potential for price volatility and manipulation due to limited regulatory oversight compared to major exchanges.
- Limited analyst coverage and institutional interest, which can restrict information flow and market efficiency.
- Challenges in raising capital through public offerings due to the perceived risks and lack of investor confidence associated with the "OTC Other" tier.
- Independently verify any available company news releases or press statements, acknowledging potential biases.
- Attempt to locate any historical financial filings, even if not regularly updated, to understand past performance.
- Research the background and track record of current management beyond what is publicly stated.
- Scrutinize the status and outcomes of Picoplatin's clinical trials through independent scientific or medical sources, if available.
- Assess the company's funding status and burn rate, as a $0.00B market cap suggests limited financial resources.
- Understand the competitive landscape for Picoplatin's target indications and potential market barriers.
- Consult with a financial advisor experienced in OTC and microcap investments.
- The company has a long operational history, founded in 1984 as NeoRx Corporation, indicating longevity.
- It has a specific, named lead product candidate, Picoplatin, which has progressed through advanced clinical stages, including a pivotal Phase III trial.
- A named CEO, Robert F. Caspari, is identified as managing the company's operations.
- Its stated dedication to "discovery and market introduction of cancer treatments" outlines a clear, albeit ambitious, business objective.
What Investors Ask About Poniard Pharmaceuticals, Inc. (PARD) — Healthcare
What does the AI Score mean for PARD?
PARD holds an AI Score of 48/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing platinum-based cancer treatments. Its lead product candidate, Picoplatin, has advanced through pivotal Phase III …
What is Poniard Pharmaceuticals, Inc.'s primary focus and lead product?
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its primary focus is on its flagship product candidate, Picoplatin, a platinum-based therapy. Picoplatin is designed to target various cancer types, including small cell lung, colorectal, prostate, and ovarian cancers.
What is the status of Poniard Pharmaceuticals, Inc.'s clinical development pipeline?
Poniard Pharmaceuticals, Inc.'s clinical development pipeline is centered around its lead candidate, Picoplatin, a platinum-based cancer therapy. The company has completed a pivotal Phase III SPEAR trial for Picoplatin in the second-line treatment of small cell lung cancer patients. This advanced stage signifies a substantial investment in clinical validation.
What are the key operational challenges for Poniard Pharmaceuticals, Inc.?
Poniard Pharmaceuticals, Inc. faces several operational challenges inherent to its structure and market position. With a small team of 7 employees and a market capitalization of $0.00B, the company operates with limited resources, which can constrain the pace and scale of its development and commercialization efforts.
What are the key factors to evaluate for PARD?
Poniard Pharmaceuticals, Inc. (PARD) holds an AI score of 48/100 (low). presents a research-stage profile centered on its lead candidate, Picoplatin, a platinum-based therapy for various cancers. Not financial advice.
How frequently does PARD data refresh on this page?
PARD's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PARD's recent stock price performance?
Poniard Pharmaceuticals, Inc. (PARD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Dedicated focus on a single, advanced-stage product candidate, Picoplatin, across multiple cancer types. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PARD overvalued or undervalued right now?
Poniard Pharmaceuticals, Inc. (PARD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PARD before investing?
Before investing in Poniard Pharmaceuticals, Inc. (PARD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data provided beyond market capitalization, beta, and dividend yield.
- Specific future clinical trial milestones, outcomes, and timelines are not detailed in the source material.
- CEO background information is limited to name and employee count, without further career history.